Regulatory approval: targeted protein degradation enters first FDA-backed oncology use

Vepdegestrant (Veppanu) — an oral CRBN-recruiting PROTAC from Array/ARV-471 — became the first FDA-approved PROTAC therapy in May 2026, marking a regulatory milestone for targeted protein degradation in oncology. The approval package is tied to efficacy against estrogen receptor–positive disease driven by both wild-type and ESR1-mutant ERα.